MOKAN Wealth Management Inc. Grows Position in Johnson & Johnson $JNJ

MOKAN Wealth Management Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 19.0% in the second quarter, HoldingsChannel.com reports. The firm owned 14,115 shares of the company’s stock after buying an additional 2,250 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of MOKAN Wealth Management Inc.’s holdings, making the stock its 24th largest holding. MOKAN Wealth Management Inc.’s holdings in Johnson & Johnson were worth $2,156,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth $48,000. Finally, von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the first quarter worth $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $190.88 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.70 billion, a P/E ratio of 20.41, a P/E/G ratio of 2.40 and a beta of 0.40. The business has a fifty day simple moving average of $179.28 and a two-hundred day simple moving average of $164.16. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion during the quarter. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Morgan Stanley raised their price target on Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Citigroup raised their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $193.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.